CoChat

Second-generation antipsychotics for major depressive disorder and dysthymia

Open access
Komossa, Katja, Depping, Anna M, Gaudchau, Andrea, Kissling, Werner, Leucht, Stefan · 2010 · Cochrane Database of Systematic Reviews
Cited by 171

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Major depressive disorder (MDD) is a common condition with a lifetime prevalence of 15% to 18%, which leads to considerable suffering and disability. Some antipsychotics have been reported to induce remission in major depression, when added to an antidepressant. OBJECTIVES: To evaluate the effects of second-generation antipsychotic (SGA) drugs (alone or augmentation) compared with placebo or antidepressants for people with MDD or dysthymia. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on clinicaltrials.gov and contacted key authors and drug companies. SELECTION CRITERIA: We included all randomised, double-blind trials comparing oral SGA treatment (alone or augmentation) with other forms of pharmaceutical treatment or placebo in people with MDD or dysthymia. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated the odds ratio (OR) and 95% confidence interval (CI) on an intention-to-treat basis, and for continuous data the mean difference (MD), based on a random-effects model. We presented each comparison separately; we did not perform a pooled data analysis. MAIN RESULTS: We included 28 trials with 8487 participants on five SGAs: amisulpride, aripiprazole, olanzapine, quetiapine and risperidone.Three studies (1092 participants) provided data on aripiprazole augmentation in MDD. All efficacy data (response n = 1092, three RCTs, OR 0.48; 95% CI 0.37 to 0.63), (MADRS n = 1077, three RCTs, MD -3.04; 95% CI -4.09 to -2) indicated a benefit for aripiprazole but more side effects (weight gain, EPS) .Seven trials (1754 participants) reported data on olanzapine. Compared to placebo fewer people discontinued treatment due to inefficacy; compared to antidepressants there were no efficacy differences, olanzapine augmentation showed symptom reduction (MADRS n = 808, five RCTs, MD -2.84; 95% CI -5.48 to -0.20), but also more weight or prolactin increase.Quetiapine data are based on seven trials (3414 participants). Compared to placebo, quetiapine monotherapy (response n = 1342, three RCTs, OR 0.52; 95% CI 0.41 to 0.66) and quetiapine augmentation (response n = 937, two RCTs, OR 0.68; 95% CI 0.52 to 0.90) showed symptom reduction, but quetiapine induced more sedation.Four trials (637 participants) presented data on risperidone augmentation, response data were better for risperidone (n = 371, two RCTs, OR 0.57; 95% CI 0.36 to 0.89) but augmentation showed more prolactin increase and weight gain.Five studies (1313 participants) presented data on amisulpride treatment for dysthymia. There were some beneficial effects compared to placebo or antidepressants but tolerability was worse. AUTHORS' CONCLUSIONS: Quetiapine was more effective than placebo treatment. Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo. Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people. Most SGAs showed worse tolerability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008121.pub2

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 73

  1. Amore, 2001, Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study, International Clinical Psychopharmacology, 16, 317, 10.1097/00004850-200111000-00001 · DOI
  2. Bauer M Pretorius H Earley W Lindgren P Brecher M Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD) 7th International Forum on Mood and Anxiety Disorders 2007 · doi:10.1016/j.eurpsy.2008.01.463
  3. Berman, 2007, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study, Journal of Clinical Psychiatry, 68, 843, 10.4088/JCP.v68n0604 · DOI · Paper page
  4. Boyer, 1996, Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine, versus amineptine, European Psychiatry, 11, 135, 10.1016/0924-9338(96)85188-1 · DOI
  5. Boyer, 1999, Amisulpride versus amineptine and placebo for the treatment of dysthymia, Neuropsychobiology, 39, 25, 10.1159/000026556 · DOI
  6. Cassano, 2002, Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study, International Clinical Psychopharmacology, 17, 27, 10.1097/00004850-200201000-00004 · DOI
  7. Costa-E-Silva, 1990, Treatment of dysthymic disorder with low-dose amisulpride, Annales de Psychiatrie, 3, 242
  8. Cutler, 2009, Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study, Journal of Clinical Psychiatry, 70, 526, 10.4088/JCP.08m04592 · DOI
  9. Montgomery S Cutler A Lazarus A Schollin M Brecher M A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) 7th International Forum on Mood and Anxiety Disorders 2007 · doi:10.1016/j.eurpsy.2008.01.518
  10. Datto C Lam R Lepola U Sweitzer D Eriksson H Brecher M Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD) 161st Annual Meeting of the American Psychiatric Association 2008 · doi:10.1016/s0924-977x(08)70540-6
  11. Lecrubier, 1997, Amisulpride versus imipramine and placebo in dysthymia and major depression, Journal of Affective Disorders, 43, 95, 10.1016/S0165-0327(96)00103-6 · DOI
  12. Alexopoulos, 2008, Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression, American Journal of Geriatric Psychiatry, 16, 21, 10.1097/JGP.0b013e31813546f2 · DOI
  13. Gharabawi, 2004, Remission and maintenance effect of risperidone augmentation for older patients with resistant depression, Neuropsychopharmacology, 29, 87
  14. Mahmoud, 2007, Risperidone for treatment-refractory major depressive disorder: a randomized trial, Annals of Internal Medicine, 147, 593, 10.7326/0003-4819-147-9-200711060-00003 · DOI · Paper page
  15. Nemeroff, 2004, Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial, Neuropsychopharmacology, 29, 159
  16. Rapaport, 2006, Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation, Neuropsychopharmacology, 31, 2505, 10.1038/sj.npp.1301113 · DOI
  17. Ravizza, 1999, Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline, Journal of Psychopharmacology, 13, 248, 10.1177/026988119901300307 · doi:10.1177/026988119901300307
  18. Rothschild, 2004, A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features, Journal of Clinical Psychopharmacology, 24, 365, 10.1097/01.jcp.0000130557.08996.7a · DOI
  19. Rothschild, 2004, A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features, Journal of Clinical Psychopharmacology, 24, 365, 10.1097/01.jcp.0000130557.08996.7a · DOI
  20. Shelton, 2001, A novel augmentation strategy for treating resistant major depression, American Journal of Psychiatry, 158, 131, 10.1176/appi.ajp.158.1.131 · DOI · Paper page
  21. Smeraldi, 1998, Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission, Journal of Affective Disorders, 48, 47, 10.1016/S0165-0327(97)00139-0 · DOI
  22. Thase, 2007, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder, Journal of Clinical Psychiatry, 68, 224, 10.4088/JCP.v68n0207 · DOI · Paper page
  23. Weisler R Joyce M McGill L Lazarus A Aström M Brecher M Extended release quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study 161st Annual Meeting of the American Psychiatric Association 2008 · DOI
  24. Barbee, 2004, The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder, Journal of Clinical Psychiatry, 65, 975, 10.4088/JCP.v65n0714 · DOI
  25. Bellino, 1997, An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly, Current Therapeutic Research, 58, 798, 10.1016/S0011-393X(97)80113-0 · DOI
  26. Bogetto, 1997, Pharmacological treatment of dysthymia: a clinical trial, Rivista di Psichiatria, 32, 1
  27. Cao, 2005, Controlled study of venlafaxine combined with quetiapine in refractory depression, Journal of Clinical Psychosomatic Diseases, 11, 129
  28. Deng, 2006, A control study of citalopram combined with quetiapine in the treatment of female depression, Journal of Clinical Psychosomatic Diseases, 12, 247
  29. Liu, 2005, A clinical observation of the effect of paroxetine with small-dose olanzapine in depression, Shanghai Archives of Psychiatry, 17, 268
  30. Liu, 2005, Effect and safety of the treatment for comorbid anxiety and depression by use of short term and low dose olanzapine in combination with fluoxetine, Chinese Journal of Clinical Rehabilitation, 9, 6
  31. Meyers, 2009, A double- blind randomised controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression, Archives of General Psychiatry, 66, 838, 10.1001/archgenpsychiatry.2009.79 · DOI · Paper page
  32. Muller-Siecheneder, 1998, Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome, Journal of Clinical Psychopharmacology, 18, 111, 10.1097/00004714-199804000-00003 · DOI
  33. Papakostas, 2004, Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder, Journal of Clinical Psychiatry, 65, 217, 10.4088/JCP.v65n0212 · DOI
  34. Qu, 2005, Improvement of sleep and anxiety in patients with major depression with fluoxetine combined with small dose of olanzapine, Chinese Journal of Clinical Rehabilitation, 9, 254
  35. Rocca, 2002, A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder, Journal of Affective Disorders, 70, 313, 10.1016/S0165-0327(01)00327-5 · DOI
  36. Schaffer, 2008, Correlates of suicidality among patients with psychotic depression, Suicide and Life Threatening Behaviour, 38, 403, 10.1521/suli.2008.38.4.403 · DOI
  37. Shelton, 2005, Risperidone vs. bupropion combined with SSRIs in treatment resistant unipolar major depression, Neuropsychopharmacology, 30, 238
  38. Simon, 2005, Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder, Journal of Clinical Psychiatry, 66, 1216, 10.4088/JCP.v66n1002 · DOI
  39. Song, 2007, Venlafaxine combined with low dose risperidone for treatment-resistant depression, Journal of Clinical Rehabilitative Tissue Engineering Research, 11, 10486
  40. Yang, 2006, Curative effect of paroxetine combined with quetiapine in treating depression, Occupational Health, 22, 548
  41. Ye, 2004, A study of the effect of small dose risperidone in depression without psychotic symptoms, Shandong Archives of Psychiatry, 17, 9
  42. Zanardi, 2006, A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia, European Neuropsychopharmacology, 16, 281, 10.1016/j.euroneuro.2005.10.005 · DOI
  43. Zhou, 2004, Clinical study on treatment of depression with risperidone combined with venlafaxine, Medical Journal of National Defending Forces in North China, 16, 85
  44. Anderson, 2008, Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines, Journal of Psychopharmacology, Epub, 1
  45. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III)
  46. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition- Revised (DSM-III-R)
  47. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
  48. Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 63, 10.1016/S0893-133X(97)00112-7 · DOI · Paper page
  49. Barbui, 2004, Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice, Acta Psychiatrica Scandinavica, 109, 275, 10.1111/j.1600-0447.2003.00283.x · DOI
  50. Berger, 2004, Psychische Erkrankungen. Klinik und Therapie
  51. Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
  52. Cipriani, 2007, Paroxetine versus other anti-depressive agents for depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006531 · DOI
  53. Correll, 2004, Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies, American Journal of Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 · DOI · Paper page
  54. Debattista, 2009, Utility of atypical antipsychotics in the treatment of resistant unipolar depression, CNS Drugs, 23, 369, 10.2165/00023210-200923050-00002 · DOI
  55. Der-Simonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  56. Domino, 2008, Who are the new users of antipsychotic medications?, Psychiatric Services, 59, 507, 10.1176/ps.2008.59.5.507 · DOI
  57. Gayetot, 2007, When depression does not end. Resistant depression: recent clinical and therapeutic aspects, Review Medical de Liege, 62, 103
  58. Goodwin, 2009, Advantages and disadvantages of combination treatment with antipsychotics: ECNP Consensus Meeting, March 2008, Nice, European Neuropsychopharmacology, 19, 520, 10.1016/j.euroneuro.2009.04.003 · DOI
  59. Gulliford, 1999, Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
  60. Guy, 1976, Clinical Global Impressions - ECDEU Assessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
  61. Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
  62. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  63. Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008 · DOI · Paper page
  64. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  65. Nelson, 2009, Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials, American Journal of Psychiatry, 166, 980, 10.1176/appi.ajp.2009.09030312 · DOI · Paper page
  66. Papakostas, 2007, Augmentation of antidepressants with atypical antipsychotic medication for treatment-resistant major depressive disorder: a meta-analysis, Journal of Clinical Psychiatry, 68, 826, 10.4088/JCP.v68n0602 · DOI · Paper page
  67. Ravindran, 2007, Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders, Expert Opinion in Pharmacotherapy, 8, 1693, 10.1517/14656566.8.11.1693 · DOI
  68. Sajatovic, 2003, Treatment for mood and anxiety disorders: quetiapine and aripiprazole, Current Psychiatry Reports, 5, 320, 10.1007/s11920-003-0062-9 · DOI
  69. Vital, 2007, Seroquel led antipsychotics sales in 2006, Clinical Psychiatric News, 35, 1
  70. World Health Organization, 1992, International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)
  71. World Health Organization, 2005, The European Health Report 2005
  72. Wijkstra, 2006, Pharmacologic treatment for unipolar psychotic depression, British Journal of Psychiatry, 188, 410, 10.1192/bjp.bp.105.010470 · DOI
  73. Yatham, 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action, Journal of Clinical Psychiatry, 66 (Suppl 5), 40

Cited by

Metadata

Authors
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-12-08
Volume
2012
Issue
2
Pages
CD008121-CD008121
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1929751478
Cited by
171
References
22
FWCI
10.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.